A new first-in-class therapy for canine lymphoma is being developed by a collaboration between Aurelius Biotherapeutics and Lytix Biopharma a human immunotherapy development company. The two companies realized they were a good fit when the CEO’s met at the SITC immunotherapy conference in 2019. The past year has been spent finalizing the terms of the agreement and planning the first stages of development.
“ Our partnership with Lytix Biopharma is a big step forward in the treatment of lymphoma in our canine companions. Lytix is the leader in developing oncolytic molecules and their expertise in this field is invaluable to this therapy.” Theresa Westfall, CEO of Aurelius Biotherapeutics
Aurelius Biotherapeutics will use the technology that Lytix Biopharma has developed to improve the responses to the immunotherapy they currently provide for the treatment of canine lymphoma. The companies will use their leading products together to combine the oncolytic properties of the peptide molecules with the immunotherapy of adoptive T cells to fill the unmet goal of long-term survival in canine lymphoma. Valuable information regarding the synergism of the two products will be gained and will lend insight towards future therapies for both humans and dogs.
Theresa Westfall, DVM, CEO
Aurelius Biotherapeutics